Ellagic Acid Prevents Cisplatin‐Induced Oxidative Stress in Liver and Heart Tissue of Rats
: Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and several studies suggest that supplemental antioxidants can reduce cisplatin‐induced hepatotoxicity. The present study was designed to determ...
Saved in:
Published in | Basic & clinical pharmacology & toxicology Vol. 101; no. 5; pp. 345 - 349 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Malden, USA
Blackwell Publishing Inc
01.11.2007
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | : Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and several studies suggest that supplemental antioxidants can reduce cisplatin‐induced hepatotoxicity. The present study was designed to determine the effects on the liver and heart oxidant/antioxidant system and the possible protective effects of ellagic acid on liver and heart toxicity induced by cisplatin. The control group received 0.9% saline; animals in the ellagic acid group received only ellagic acid (10 mg/kg); animals in the cisplatin group received only cisplatin (7 mg/kg); animals in cisplatin + ellagic acid group received ellagic acid for 10 days after cisplatin. The rats were killed at the end of the treatment period. Malondialdehyde (MDA) and glutathione (GSH) levels, glutathione‐peroxidase (GSH‐Px) and catalase (CAT) activities were determined in liver and heart tissue. While administration of cisplatin increased the MDA levels in liver and heart tissues, it decreased the GSH, GSH‐Px and CAT in these samples when compared to the control group. The administration of ellagic acid to cisplatin‐treated rats decreased the MDA levels, and increased GSH, GSH‐Px and CAT in these samples. Cisplatin caused marked damages in the histopathological status of liver and heart tissues. These damages were ameliorated by ellagic acid administration. In conclusion, ellagic acid may be used in combination with cisplatin in chemotherapy to improve cisplatin‐induced oxidative stress parameters. |
---|---|
AbstractList | Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and several studies suggest that supplemental antioxidants can reduce cisplatin-induced hepatotoxicity. The present study was designed to determine the effects on the liver and heart oxidant/antioxidant system and the possible protective effects of ellagic acid on liver and heart toxicity induced by cisplatin. The control group received 0.9% saline; animals in the ellagic acid group received only ellagic acid (10 mg/kg); animals in the cisplatin group received only cisplatin (7 mg/kg); animals in cisplatin + ellagic acid group received ellagic acid for 10 days after cisplatin. The rats were killed at the end of the treatment period. Malondialdehyde (MDA) and glutathione (GSH) levels, glutathione-peroxidase (GSH-Px) and catalase (CAT) activities were determined in liver and heart tissue. While administration of cisplatin increased the MDA levels in liver and heart tissues, it decreased the GSH, GSH-Px and CAT in these samples when compared to the control group. The administration of ellagic acid to cisplatin-treated rats decreased the MDA levels, and increased GSH, GSH-Px and CAT in these samples. Cisplatin caused marked damages in the histopathological status of liver and heart tissues. These damages were ameliorated by ellagic acid administration. In conclusion, ellagic acid may be used in combination with cisplatin in chemotherapy to improve cisplatin-induced oxidative stress parameters. Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and several studies suggest that supplemental antioxidants can reduce cisplatin‐induced hepatotoxicity. The present study was designed to determine the effects on the liver and heart oxidant/antioxidant system and the possible protective effects of ellagic acid on liver and heart toxicity induced by cisplatin. The control group received 0.9% saline; animals in the ellagic acid group received only ellagic acid (10 mg/kg); animals in the cisplatin group received only cisplatin (7 mg/kg); animals in cisplatin + ellagic acid group received ellagic acid for 10 days after cisplatin. The rats were killed at the end of the treatment period. Malondialdehyde (MDA) and glutathione (GSH) levels, glutathione‐peroxidase (GSH‐Px) and catalase (CAT) activities were determined in liver and heart tissue. While administration of cisplatin increased the MDA levels in liver and heart tissues, it decreased the GSH, GSH‐Px and CAT in these samples when compared to the control group. The administration of ellagic acid to cisplatin‐treated rats decreased the MDA levels, and increased GSH, GSH‐Px and CAT in these samples. Cisplatin caused marked damages in the histopathological status of liver and heart tissues. These damages were ameliorated by ellagic acid administration. In conclusion, ellagic acid may be used in combination with cisplatin in chemotherapy to improve cisplatin‐induced oxidative stress parameters. : Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and several studies suggest that supplemental antioxidants can reduce cisplatin‐induced hepatotoxicity. The present study was designed to determine the effects on the liver and heart oxidant/antioxidant system and the possible protective effects of ellagic acid on liver and heart toxicity induced by cisplatin. The control group received 0.9% saline; animals in the ellagic acid group received only ellagic acid (10 mg/kg); animals in the cisplatin group received only cisplatin (7 mg/kg); animals in cisplatin + ellagic acid group received ellagic acid for 10 days after cisplatin. The rats were killed at the end of the treatment period. Malondialdehyde (MDA) and glutathione (GSH) levels, glutathione‐peroxidase (GSH‐Px) and catalase (CAT) activities were determined in liver and heart tissue. While administration of cisplatin increased the MDA levels in liver and heart tissues, it decreased the GSH, GSH‐Px and CAT in these samples when compared to the control group. The administration of ellagic acid to cisplatin‐treated rats decreased the MDA levels, and increased GSH, GSH‐Px and CAT in these samples. Cisplatin caused marked damages in the histopathological status of liver and heart tissues. These damages were ameliorated by ellagic acid administration. In conclusion, ellagic acid may be used in combination with cisplatin in chemotherapy to improve cisplatin‐induced oxidative stress parameters. |
Author | Yüce, Abdurrauf Aksakal, Mesut Ateşşahin, Ahmet Çeribaşı, Ali Osman |
Author_xml | – sequence: 1 givenname: Abdurrauf surname: Yüce fullname: Yüce, Abdurrauf – sequence: 2 givenname: Ahmet surname: Ateşşahin fullname: Ateşşahin, Ahmet – sequence: 3 givenname: Ali Osman surname: Çeribaşı fullname: Çeribaşı, Ali Osman – sequence: 4 givenname: Mesut surname: Aksakal fullname: Aksakal, Mesut |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19179500$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17910619$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkM1OGzEQgC1EVf76CsgXesvWf5tdH3qgEQWkSKCS3ipZXnu2crTxBs8uDbc-Qp-RJ6nTRHCtLx6Pvxl7vhNyGPsIhFDOCp7Xp2XBKyUmVa1kIRirCsa40MXmgBy_Xhy-xrI8IieIS8ZEpTh7T454pTmbcn1Mflx1nf0ZHL10wdP7BE8QB6SzgOvODiG-_P5zG_3owNO7TfA59QT0YUiASEOk83xM1EZPb8CmgS4C4gi0b-k3O-AZedfaDuHDfj8l379eLWY3k_nd9e3scj5xpVJ60k5tXTdK6NrzChrVCGl1XdWsaploG-m4VlPQrSulB8ed1dKpRvOc8yAB5Cn5uOu7Tv3jCDiYVUAHebII_YhG5GFFyacZrHegSz1igtasU1jZ9Gw4M1uzZmm20sxWoNmaNf_Mmk0uPd-_MTYr8G-Fe5UZuNgDFp3t2mSjC_jG6UyWjGXu8477FTp4_u8PmC-z-0WO5F_MZ5bo |
CitedBy_id | crossref_primary_10_1016_j_pharep_2018_02_007 crossref_primary_10_1016_j_phymed_2019_152921 crossref_primary_10_1016_j_lfs_2022_121313 crossref_primary_10_3923_ijcr_2016_176_187 crossref_primary_10_1038_s41419_023_05645_y crossref_primary_10_3390_md18020105 crossref_primary_10_1016_j_ejphar_2022_175316 crossref_primary_10_1080_19390211_2019_1634175 crossref_primary_10_1007_s00210_024_03207_3 crossref_primary_10_1177_0748233710395993 crossref_primary_10_1111_jfbc_13190 crossref_primary_10_1177_0960327111428957 crossref_primary_10_1007_s00210_016_1258_y crossref_primary_10_1007_s11010_017_3162_2 crossref_primary_10_1080_01480545_2023_2242008 crossref_primary_10_1007_s11356_019_07352_8 crossref_primary_10_1111_j_1742_7843_2010_00571_x crossref_primary_10_1016_j_phrs_2020_104655 crossref_primary_10_1515_sjecr_2016_0059 crossref_primary_10_1016_j_jaim_2017_11_002 crossref_primary_10_4274_tjps_galenos_2021_84555 crossref_primary_10_3390_ijms13021790 crossref_primary_10_3390_toxics3030304 crossref_primary_10_1186_1472_6882_12_111 crossref_primary_10_1007_s11010_019_03541_8 crossref_primary_10_1007_s12012_018_9446_2 crossref_primary_10_1016_j_prostaglandins_2019_04_002 crossref_primary_10_3389_fphar_2016_00350 crossref_primary_10_1080_01616412_2019_1576319 crossref_primary_10_3389_fphar_2019_01681 crossref_primary_10_1002_jbt_23309 crossref_primary_10_1007_s00210_017_1387_y crossref_primary_10_1111_bcpt_12443 crossref_primary_10_3923_ijp_2019_465_477 crossref_primary_10_1515_sjecr_2017_0053 crossref_primary_10_1016_j_phymed_2023_154867 crossref_primary_10_2478_sjecr_2019_0029 crossref_primary_10_3923_pjbs_2010_463_479 crossref_primary_10_1016_j_toxrep_2015_07_009 crossref_primary_10_1007_s11064_023_04059_8 crossref_primary_10_3109_01480545_2011_589445 crossref_primary_10_1007_s11010_012_1250_x crossref_primary_10_1080_09168451_2019_1576498 crossref_primary_10_3390_biomedicines5020018 crossref_primary_10_1177_0960327110390064 crossref_primary_10_1016_j_jff_2014_07_011 crossref_primary_10_1007_s00210_024_02956_5 crossref_primary_10_1073_pnas_2006883117 crossref_primary_10_1007_s11033_014_3292_5 crossref_primary_10_1016_j_bbrc_2013_03_100 crossref_primary_10_1016_j_intimp_2009_10_013 crossref_primary_10_1007_s10953_012_9938_9 crossref_primary_10_1080_14756366_2016_1220378 crossref_primary_10_1016_j_biomag_2014_01_008 crossref_primary_10_1016_j_jff_2015_07_004 crossref_primary_10_1080_15376516_2022_2137870 crossref_primary_10_1080_13880209_2022_2074051 crossref_primary_10_1093_jas_skac301 crossref_primary_10_3923_ijp_2024_383_393 crossref_primary_10_1186_s12885_016_2370_6 crossref_primary_10_3390_molecules26164800 crossref_primary_10_1016_j_sjbs_2022_01_052 crossref_primary_10_1016_j_eujim_2016_11_006 crossref_primary_10_1016_j_fct_2009_02_007 crossref_primary_10_1007_s11010_018_3310_3 crossref_primary_10_1007_s10616_013_9589_8 crossref_primary_10_1002_tox_23097 crossref_primary_10_1080_01913123_2016_1203854 crossref_primary_10_7762_cnr_2022_11_2_98 crossref_primary_10_1515_jbcpp_2019_0073 crossref_primary_10_1002_cam4_2072 crossref_primary_10_1016_j_arcmed_2015_08_005 crossref_primary_10_1007_s00394_012_0358_9 crossref_primary_10_1016_j_ejphar_2022_175362 crossref_primary_10_3389_fmicb_2021_793576 crossref_primary_10_1016_j_etp_2010_11_004 crossref_primary_10_1155_2022_3848084 crossref_primary_10_1007_s00441_024_03902_w crossref_primary_10_1111_j_1742_7843_2008_00284_x crossref_primary_10_1007_s11250_022_03222_7 crossref_primary_10_1088_1755_1315_1271_1_012079 crossref_primary_10_1002_cbdv_202301719 crossref_primary_10_1016_j_fct_2014_07_022 crossref_primary_10_1016_j_jphs_2020_01_007 crossref_primary_10_3390_ijms21207753 crossref_primary_10_15407_ubj87_01_099 crossref_primary_10_1016_j_phrs_2015_04_008 crossref_primary_10_52547_phypha_26_4_4 crossref_primary_10_1071_RD09078 crossref_primary_10_3389_fphar_2017_00196 crossref_primary_10_1007_s12012_011_9138_7 crossref_primary_10_1016_j_phymed_2017_05_007 crossref_primary_10_1016_j_scitotenv_2019_136338 crossref_primary_10_1089_jmf_2013_0013 crossref_primary_10_1016_j_ijpharm_2015_03_071 crossref_primary_10_1016_j_toxlet_2015_11_028 crossref_primary_10_3390_cancers13092032 |
Cites_doi | 10.1016/S1043-6618(03)00040-9 10.1007/s002040050444 10.1016/S0021-9258(19)52451-6 10.1023/A:1008407014084 10.1006/phrs.2001.0860 10.1006/taap.1997.8325 10.1111/j.1742-7843.2006.00015.x 10.1021/jf011275g 10.1016/0003-2697(68)90092-4 10.1159/000048864 10.1002/jbt.20030 10.1016/S0027-5107(97)00245-5 10.1007/s002800000127 10.1021/np0498051 10.1016/S0006-2952(03)00413-1 10.1016/j.theriogenology.2004.10.003 10.1016/j.jnutbio.2005.01.006 10.1016/j.ejphar.2006.01.007 10.1093/ndt/12.12.2478 10.1016/0006-291X(76)90747-6 10.1002/jat.889 10.1016/S0300-483X(97)00127-3 10.1016/S0278-6915(99)00021-6 10.1006/phrs.2000.0724 10.1006/phrs.1999.0600 10.1111/j.1600-079X.2006.00327.x 10.1016/j.tox.2005.10.015 10.1007/978-1-4684-5730-8_13 10.1016/S1043-6618(03)00010-0 10.1016/0003-2697(66)90167-9 10.1016/j.foodchem.2005.05.033 10.1207/S15327914NC3701_1 10.1016/j.tox.2003.10.012 10.1016/S0014-2999(02)01537-6 10.1006/phrs.2001.0822 10.1016/j.foodchem.2004.02.003 10.1016/S0305-7372(97)90012-8 10.1016/j.reprotox.2005.05.003 10.1016/S0027-5107(98)00158-4 10.1016/B978-0-12-091302-2.50032-3 |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U7 C1K |
DOI | 10.1111/j.1742-7843.2007.00129.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE CrossRef Toxicology Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1742-7843 |
EndPage | 349 |
ExternalDocumentID | 10_1111_j_1742_7843_2007_00129_x 17910619 19179500 BCPT129 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAYOK AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EDH EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YCJ ~IA ~WT 08R AAVGM ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U7 C1K |
ID | FETCH-LOGICAL-c5449-f6a88b4298d17eb4b23a987807f02fb3c1946e9fc53dec1ca93c4b916e9de3ee3 |
IEDL.DBID | DR2 |
ISSN | 1742-7835 |
IngestDate | Fri Aug 16 02:01:46 EDT 2024 Fri Aug 23 03:31:54 EDT 2024 Sat Sep 28 07:48:09 EDT 2024 Sun Oct 22 16:03:31 EDT 2023 Sat Aug 24 01:07:19 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Antineoplastic agent Heart Oxidative stress Hemostatic Rat Digestive system Antimutagen Liver Rodentia Cisplatin Prevention Alkylating agent Vertebrata Mammalia Ellagic acid Animal Circulatory system Platinum II Complexes |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5449-f6a88b4298d17eb4b23a987807f02fb3c1946e9fc53dec1ca93c4b916e9de3ee3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-7843.2007.00129.x |
PMID | 17910619 |
PQID | 21062516 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_21062516 crossref_primary_10_1111_j_1742_7843_2007_00129_x pubmed_primary_17910619 pascalfrancis_primary_19179500 wiley_primary_10_1111_j_1742_7843_2007_00129_x_BCPT129 |
PublicationCentury | 2000 |
PublicationDate | November 2007 |
PublicationDateYYYYMMDD | 2007-11-01 |
PublicationDate_xml | – month: 11 year: 2007 text: November 2007 |
PublicationDecade | 2000 |
PublicationPlace | Malden, USA |
PublicationPlace_xml | – name: Malden, USA – name: Oxford – name: England |
PublicationTitle | Basic & clinical pharmacology & toxicology |
PublicationTitleAlternate | Basic Clin Pharmacol Toxicol |
PublicationYear | 2007 |
Publisher | Blackwell Publishing Inc Blackwell |
Publisher_xml | – name: Blackwell Publishing Inc – name: Blackwell |
References | 1968; 25 2004; 88 1966; 16 2006; 97 2006; 218 2002; 50 2000; 46 2007; 100 2000; 41 2004; 67 1997; 23 2005; 63 1974 2001; 44 1998; 398 2001; 64 2006; 532 2001; 43 1999 1997; 124 2006; 41 1997; 71 2004; 18 1990 2000; 37 2006; 21 2004; 195 1976; 71 1999; 37 1997; 12 2002; 442 1951; 193 2003; 47 1998; 149 2005; 16 1998; 421 1998; 9 2003; 66 2003; 23 e_1_2_5_26_2 e_1_2_5_27_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 e_1_2_5_42_2 Ateşşahin A (e_1_2_5_40_2) 2007; 100 e_1_2_5_28_2 e_1_2_5_29_2 e_1_2_5_41_2 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_13_2 e_1_2_5_38_2 e_1_2_5_9_2 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_36_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_34_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_2_2 Halliwell B (e_1_2_5_33_2) 1999 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_39_2 e_1_2_5_19_2 e_1_2_5_30_2 |
References_xml | – volume: 398 start-page: 183 year: 1998 end-page: 7 article-title: Inhibitory effects of ellagic acid on the direct‐acting mutagenicity of aflatoxin B in the Salmonella microsuspension assay publication-title: Mutat Res – volume: 47 start-page: 517 year: 2003 end-page: 22 article-title: The effects of oral glutamine on cisplatin‐induced nephrotoxicity in rats publication-title: Pharmacol Res – volume: 50 start-page: 2200 year: 2002 end-page: 6 article-title: Free radical studies of ellagic acid, natural phenolic antioxidants publication-title: J Agric Food Chem – volume: 37 start-page: 1 year: 2000 end-page: 18 article-title: Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects publication-title: Nutr Cancer – volume: 37 start-page: 313 year: 1999 end-page: 8 article-title: Prevention of N‐Nitrosodiethylamine‐induced lung tumorigenesis by ellagic acid and quercetin in mice publication-title: Food Chem Toxicol – volume: 21 start-page: 42 year: 2006 end-page: 7 article-title: Protective role of lycopene on cisplatin‐induced changes in sperm characteristics, testicular damage and oxidative stress in rats publication-title: Reprod Toxicol – volume: 71 start-page: 952 year: 1976 end-page: 8 article-title: Glutathione peroxidase activity in selenium‐deficient rat liver publication-title: Bioch Bioph Res Commun – volume: 124 start-page: 27 year: 1997 end-page: 37 article-title: Modulation of TCDD‐induced fetotoxicity and oxidative stress in embriyonic and placental tissues of C57BL/6J mice by vitamin E succinate and ellagic acid publication-title: Toxicology – start-page: 188 year: 1999 end-page: 276 – volume: 218 start-page: 164 year: 2006 end-page: 71 article-title: Protective effect of lycopene on adriamycin‐induced cardiotoxicity and nephrotoxicity publication-title: Toxicology – volume: 41 start-page: 405 year: 2000 end-page: 11 article-title: Protective effects of vitamin C against cisplatin‐induced nephrotoxicity and lipid peroxidation in adult rats publication-title: Pharmacol Res – volume: 9 start-page: 1331 year: 1998 end-page: 7 article-title: Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients publication-title: Ann Oncol – volume: 195 start-page: 221 year: 2004 end-page: 30 article-title: Selenium and high dose vitamin E administration protects cisplatin‐induced oxidative damage to renal, liver and lens tissues in rats publication-title: Toxicology – volume: 442 start-page: 265 year: 2002 end-page: 72 article-title: Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats publication-title: Eur J Pharmacol – volume: 43 start-page: 145 year: 2001 end-page: 50 article-title: Effects of the antioxidants curcumin or selenium on cisplatin‐induced nephrotoxicity and lipid peroxidation in rats publication-title: Pharmacol Res – volume: 149 start-page: 24 year: 1998 end-page: 31 article-title: Metallothionein (MT)‐null mice are sensitive to cisplatin‐induced hepatotoxicity publication-title: Toxicol Appl Pharmacol – volume: 46 start-page: 74 year: 2000 end-page: 8 article-title: Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts publication-title: Cancer Chemother Pharmacol – volume: 16 start-page: 359 year: 1966 end-page: 64 article-title: Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems publication-title: Anal Biochem – volume: 43 start-page: 561 year: 2001 end-page: 6 article-title: Antioxidant action of bixin against cisplatin‐induced chromosome aberrations and lipid peroxidation in rats publication-title: Pharmacol Res – volume: 18 start-page: 196 year: 2004 end-page: 203 article-title: The modulatory effects of ellagic acid and vitamin E succinate on TCDD‐induced oxidative stress in different brain regions of rats after subchronic exposure publication-title: J Biochem Mol Toxicol – volume: 44 start-page: 317 year: 2001 end-page: 20 article-title: Effect of vitamin C supplementation against cisplatin‐induced toxicity and oxidative DNA damage in rats publication-title: Pharmacol Res – start-page: 93 year: 1990 end-page: 104 – volume: 88 start-page: 411 year: 2004 end-page: 7 article-title: Antioxidant activity and phenolic content of selected fruit seeds publication-title: Food Chem – volume: 532 start-page: 290 year: 2006 end-page: 3 article-title: Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats publication-title: Eur J Pharmacol – volume: 97 start-page: 524 year: 2006 end-page: 30 article-title: Quantification of gallic acid and ellagic acid from longan ( Lour.) seed and mango ( L.) kernel and their effects on antioxidant activity publication-title: Food Chem – volume: 100 start-page: 121 year: 2007 end-page: 6 article-title: Role of ellagic acid against cisplatin‐induced nephrotoxicity and oxidative stress in rats publication-title: Basic Clin Pharmacol Toxicol – volume: 12 start-page: 2478 year: 1997 end-page: 80 article-title: Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application publication-title: Nephrol Dial Transplant – volume: 64 start-page: 214 year: 2001 end-page: 21 article-title: Less damaging effect of whisky in rat stomachs in comparison with pure ethanol. Role of ellagic acid, the nonalcoholic component publication-title: Digestion – volume: 66 start-page: 907 year: 2003 end-page: 15 article-title: Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid‐extensive binding to protein and DNA publication-title: Biochem Pharmacol – volume: 63 start-page: 2063 year: 2005 end-page: 72 article-title: The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats publication-title: Theriogenology – volume: 67 start-page: 2096 year: 2004 end-page: 8 article-title: Bioactive compounds from the seeds of punica granatum (pomegranate) publication-title: J Nat Prod – volume: 23 start-page: 71 year: 2003 end-page: 4 article-title: Protective effects of erdosteine against doxorubicin‐induced cardioomyopathy in rats publication-title: J Appl Toxicol – volume: 16 start-page: 360 year: 2005 end-page: 7 article-title: antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice publication-title: J Nutr Biochem – volume: 41 start-page: 21 year: 2006 end-page: 7 article-title: Chemoprotective effect of melatonin against cisplatin‐induced testicular toxicity in rats publication-title: J Pineal Res – volume: 71 start-page: 677 year: 1997 end-page: 83 article-title: Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats publication-title: Arch Toxicol – volume: 47 start-page: 317 year: 2003 end-page: 22 article-title: Effects of erdosteine treatment against doxorubicin‐induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rat publication-title: Pharmacol Res – volume: 23 start-page: 209 year: 1997 end-page: 40 article-title: Free radicals and antioxidants in chemotherapy‐induced toxicity publication-title: Cancer Treat Rev – volume: 421 start-page: 139 year: 1998 end-page: 48 article-title: Vitamin C mediated protection on cisplatin induced mutagenicity in mice publication-title: Mutat Res – start-page: 673 year: 1974 end-page: 7 – volume: 25 start-page: 192 year: 1968 end-page: 205 article-title: Estimation of total, protein‐bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent publication-title: Anal Biochem – volume: 193 start-page: 265 year: 1951 end-page: 75 article-title: Protein measurement with folin phenol reagent publication-title: J Biol Chem – ident: e_1_2_5_13_2 doi: 10.1016/S1043-6618(03)00040-9 – ident: e_1_2_5_14_2 doi: 10.1007/s002040050444 – ident: e_1_2_5_32_2 doi: 10.1016/S0021-9258(19)52451-6 – ident: e_1_2_5_12_2 doi: 10.1023/A:1008407014084 – ident: e_1_2_5_16_2 doi: 10.1006/phrs.2001.0860 – start-page: 188 volume-title: Free Radicals in Biology and Medicine year: 1999 ident: e_1_2_5_33_2 contributor: fullname: Halliwell B – ident: e_1_2_5_7_2 doi: 10.1006/taap.1997.8325 – volume: 100 start-page: 121 year: 2007 ident: e_1_2_5_40_2 article-title: Role of ellagic acid against cisplatin‐induced nephrotoxicity and oxidative stress in rats publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/j.1742-7843.2006.00015.x contributor: fullname: Ateşşahin A – ident: e_1_2_5_26_2 doi: 10.1021/jf011275g – ident: e_1_2_5_31_2 doi: 10.1016/0003-2697(68)90092-4 – ident: e_1_2_5_39_2 doi: 10.1159/000048864 – ident: e_1_2_5_23_2 doi: 10.1002/jbt.20030 – ident: e_1_2_5_25_2 doi: 10.1016/S0027-5107(97)00245-5 – ident: e_1_2_5_36_2 doi: 10.1007/s002800000127 – ident: e_1_2_5_21_2 doi: 10.1021/np0498051 – ident: e_1_2_5_24_2 doi: 10.1016/S0006-2952(03)00413-1 – ident: e_1_2_5_28_2 doi: 10.1016/j.theriogenology.2004.10.003 – ident: e_1_2_5_38_2 doi: 10.1016/j.jnutbio.2005.01.006 – ident: e_1_2_5_42_2 doi: 10.1016/j.ejphar.2006.01.007 – ident: e_1_2_5_3_2 doi: 10.1093/ndt/12.12.2478 – ident: e_1_2_5_30_2 doi: 10.1016/0006-291X(76)90747-6 – ident: e_1_2_5_10_2 doi: 10.1002/jat.889 – ident: e_1_2_5_22_2 doi: 10.1016/S0300-483X(97)00127-3 – ident: e_1_2_5_37_2 doi: 10.1016/S0278-6915(99)00021-6 – ident: e_1_2_5_5_2 doi: 10.1006/phrs.2000.0724 – ident: e_1_2_5_4_2 doi: 10.1006/phrs.1999.0600 – ident: e_1_2_5_9_2 doi: 10.1111/j.1600-079X.2006.00327.x – ident: e_1_2_5_41_2 doi: 10.1016/j.tox.2005.10.015 – ident: e_1_2_5_34_2 doi: 10.1007/978-1-4684-5730-8_13 – ident: e_1_2_5_11_2 doi: 10.1016/S1043-6618(03)00010-0 – ident: e_1_2_5_27_2 doi: 10.1016/0003-2697(66)90167-9 – ident: e_1_2_5_20_2 doi: 10.1016/j.foodchem.2005.05.033 – ident: e_1_2_5_35_2 doi: 10.1207/S15327914NC3701_1 – ident: e_1_2_5_18_2 doi: 10.1016/j.tox.2003.10.012 – ident: e_1_2_5_6_2 doi: 10.1016/S0014-2999(02)01537-6 – ident: e_1_2_5_17_2 doi: 10.1006/phrs.2001.0822 – ident: e_1_2_5_19_2 doi: 10.1016/j.foodchem.2004.02.003 – ident: e_1_2_5_2_2 doi: 10.1016/S0305-7372(97)90012-8 – ident: e_1_2_5_8_2 doi: 10.1016/j.reprotox.2005.05.003 – ident: e_1_2_5_15_2 doi: 10.1016/S0027-5107(98)00158-4 – ident: e_1_2_5_29_2 doi: 10.1016/B978-0-12-091302-2.50032-3 |
SSID | ssj0027410 |
Score | 2.2416842 |
Snippet | : Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and... Cisplatin is one of the most active cytotoxic agents in the treatment of cancer. High doses of cisplatin have also been known to produce hepatotoxicity, and... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 345 |
SubjectTerms | Animals Antineoplastic Agents - antagonists & inhibitors Antineoplastic Agents - toxicity Antioxidants - metabolism Biological and medical sciences Catalase - metabolism Cisplatin - antagonists & inhibitors Cisplatin - toxicity Ellagic Acid - pharmacology Glutathione - metabolism Glutathione Peroxidase - metabolism Heart - drug effects Lipid Peroxidation - drug effects Liver - drug effects Liver - metabolism Male Malondialdehyde - metabolism Medical sciences Myocardium - metabolism Oxidation-Reduction Oxidative Stress - drug effects Pharmacology. Drug treatments Proteins - metabolism Rats Rats, Sprague-Dawley |
Title | Ellagic Acid Prevents Cisplatin‐Induced Oxidative Stress in Liver and Heart Tissue of Rats |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1742-7843.2007.00129.x https://www.ncbi.nlm.nih.gov/pubmed/17910619 https://search.proquest.com/docview/21062516 |
Volume | 101 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9tAEB5KToXS90NNm86h5BQZSbtaaY-pSTClD5M6kENB7EtgArKJZEhy6k_ob-wv6exKruOQQym96TJCOzuz881q5huA92WpM51zHXs-p5jisYs1L2SshBFOqMRJ6RucP38Rk1P-8Sw_G-qffC9Mzw_x58LNe0Y4r72DK91uOzmldXFRcrZmIqTYNfJ40vPqeXx0kt3IvdKhN9KLsPx2Uc8dL9qKVA-WqiWl1f20i7vg6Da6DeHp-BGcrxfWV6Wcj1adHpnrW5yP_2flj-HhgGLxsDe7J3DPNU9hf9rTYF8d4GzT1dUe4D5ONwTZV8_g-xHZHp24eGjmFgcSqRbH83bpK_OaXz9--okixln8ejm3gZocv4WmFpw3-MmXkqBqLE7ITTucBdvBRY0nqmufw-nx0Ww8iYcpD7HJOZdxLRQZDIXF0qaF01xnTMmyKJOiTrJaM5NKLpysTc6sM6lRkhmuCdU6aR1zjr2AnWbRuFeAkpL90nJDIMgRMNTS1owxgqxSKaEzFUG63tFq2ZN5VDeSIFJq5ZXqR3P6v_Kk1Ooygr2trd8IUqIr8ySJ4N3aFipyTf-_RTVusWoryqYpu0xFBC97E9nIFtKn4jICETb6r7-m-jCezujp9b8K7sL9cDsduinfwE53sXJvCVZ1ei84zG9znBQo |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB2hcgAJQfkqgdL6gHpqVknsOPGxXbVaYFtWJZV6QIr8FWkFyq5IVmo58RP4jfwSxk622616QIhbLo5ie8bznjPzBuBdnqtEpUyFTs8pxHhsQ8UyEUquueUyskK4AueTUz46Zx8u0ou-HZCrhen0Ia4v3Jxn-PPaObi7kF73cuR1YZYzupQixOA1QEB5H70_9fzqLLnBvuK-OtKNoenttJ473rQWqx7NZYPLVnX9Lu4CpOv41geo4yfwbTm1Li_l62DRqoH-cUv18T_NfRMe90CWHHSW9xTu2foZ7E06JeyrfVKsCruafbJHJiuN7Kvn8OUIzQ8PXXKgp4b0OlINGU6buUvOq3___OWaimhryKfLqfHq5OSzr2sh05qMXTYJkbUhI_TUlhTefMisImeybV7A-fFRMRyFfaOHUKeMibDiEm0GI2Nu4swqphIqRZ7lUVZFSaWojgXjVlQ6pcbqWEtBNVMIbK0wllpLX8JGPavtKyAC-X5umEYcZBEbKmEqSimiViElV4kMIF5uaTnv9DzKGzwIF7V0i-q6c7of87io5WUAO2t7vxqIXFekURTA7tIYSvRO98tF1na2aEok1EgwYx7AVmcjq7GZcGxcBMD9Tv_115SHw0mBT6__deAuPBgVJ-Ny_P704xt46C-rfXHlNmy03xf2LaKsVu147_kDz6YYSg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NattAEB5CCqFQ2qa_aptkDyGnyEja1Up7TJ0Yp01SkzqQQ0Hsn8AEZFPJkPTUR-gz9kk6u5LjOORQSm-6jNDOzux8s5r5BmA3z1WiUqZCx-cUYjy2oWKZCCXX3HIZWSFcg_PpGR9esE-X6WVX_-R6YVp-iNsLN-cZ_rx2Dj4z5aqTY1oXZjmjCyZCjF09xJOPGKeJs_DD8-RO8hV3zZFOhqb3q3oeeNNKqHoykzVqrWzHXTyER1fhrY9Pg2dwtVhZW5Zy1Zs3qqd_3CN9_D9Lfw5POxhLDlq724Q1W72AvVHLg32zT8bLtq56n-yR0ZIh--YlfDtC48MjlxzoiSEdi1RN-pN65krzqt8_f7mRItoa8uV6Yjw3Ofnqu1rIpCInrpaEyMqQIfppQ8beeMi0JOeyqV_BxeBo3B-G3ZiHUKeMibDkEi0G42Ju4swqphIqRZ7lUVZGSamojgXjVpQ6pcbqWEtBNVMIa60wllpLX8N6Na3sWyACs_3cMI0oyCIyVMKUlFLErEJKrhIZQLzY0WLWsnkUd7IgVGrhlOpmc7rf8qjU4jqA7ZWtXwpipivSKApgZ2ELBfqm--EiKzud1wWm05hexjyAN62JLGUz4XJxEQD3G_3XX1N87I_G-PTuXwV3YGN0OChOjs8-v4fH_qbad1Z-gPXm-9xuIcRq1Lb3nT9mxRb5 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ellagic+Acid+Prevents+Cisplatin-Induced+Oxidative+Stress+in+Liver+and+Heart+Tissue+of+Rats&rft.jtitle=Basic+%26+clinical+pharmacology+%26+toxicology&rft.au=Yuce%2C+Abdurrauf&rft.au=Atessahin%2C+Ahmet&rft.au=Ceribasi%2C+Ali+Osman&rft.au=Aksakal%2C+Mesut&rft.date=2007-11-01&rft.issn=1742-7835&rft.eissn=1742-7843&rft.volume=101&rft.issue=5&rft.spage=345&rft.epage=349&rft_id=info:doi/10.1111%2Fj.1742-7843.2007.00129.x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-7835&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-7835&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-7835&client=summon |